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Abstract
Hemodynamic care during postoperative management of myocardial
revascularization should include vasorelaxing drugs to insure ad-
equate graft and coronary flow, and stimulation of stroke volume to
maintain vascular perfusion pressure. We tested the cardiac (inotropic
and lusitropic) and vascular (relaxant) effects of diltiazem (0.1 nM to
0.1 mM), dobutamine (10 µM to 10 mM) and amrinone (10 µM to 1
mM) on isolated rat atria and thoracic aorta, and also on isolated
human saphenous vein (HSV) and human mammary artery (HMA).
Dobutamine produced a maximal positive inotropic effect (+dF/dtmax
= 29 ± 7%) at its ED50 for aortic relaxation (88 ± 7 µM). Conversely,
at their ED50 for aortic relaxation diltiazem depressed myocardial
contractility and amrinone did not exhibit myocardial effects. In HSV
and HMA contracted with 80 mM potassium, diltiazem and dobuta-
mine (but not amrinone) had a vasorelaxant activity similar to that in
rat aorta. Norepinephrine-contracted human vessels were significant-
ly more sensitive than potassium-contracted vessels to the relaxant
effect of amrinone (ED50 HMA = 15 ± 5 µM, ED50 HSV = 72 ± 31 µM,
P < 0.05). We conclude that at concentrations still devoid of myocar-
dial effects dobutamine and amrinone are effective dilators in graft
segment vessels and rat aorta contracted by membrane depolarization.
If the difference between aortic and myocardial tissue still holds in
human tissues, at the appropriate concentrations these drugs should be
expected to improve cardiac performance while still contributing to
the maintenance of graft patency.
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Introduction
The postoperative management of patients
who undergo open heart surgery and receive
autologous bypass grafts may require the use
of vasodilating drugs to maintain adequate
coronary and graft perfusion flow. Usually,
these patients also present left ventricular
dysfunction and, if graft vasospasm devel-
ops, the use of vasodilators with negative
inotropic effects, i.e., calcium channel
blockers, angiotensin-converting enzyme in-
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hibitors or long-lasting nitrates, might cause
further impairment of myocardial contractil-
ity. On the other hand, these patients, often
hypotensive and hypoperfused during the
immediate postoperative period, are treated
with vasoconstrictors such as norepineph-
rine that would reduce graft and coronary
perfusion. Therefore, the drugs of choice to
treat the hemodynamic malfunction of these
patients seem to be those that cause: i) vaso-
relaxation to maintain adequate graft and
coronary flow, and ii) stimulation of cardiac
stroke volume to maintain vascular perfu-
sion pressure.
Phosphodiesterase type III (PDE-III)
inhibitors and dobutamine are used clini-
cally as vasodilating and myocardial posi-
tive inotropic drugs. They share at least one
intracellular signaling pathway, the eleva-
tion of intracellular levels of cAMP, to pro-
duce both vascular and cardiac effects. Since
species and vessel specificity has been re-
ported for the vascular effects of PDE-III
inhibitors (1) it is of potential clinical impor-
tance to evaluate the responsiveness of ves-
sels used as coronary grafts to these drugs.
Milrinone has been reported to be a strong
vasodilator in human mammary artery
(HMA) contracted either with high external
potassium or with other receptor-mediated
agonists (2). In rat aorta and in HMA, relax-
ation induced by milrinone has been demon-
strated to be endothelium-independent; while
amrinone has both endothelium-dependent
and -independent vasodilatory effects in rat
aorta (3), as well as in the human forearm
vessels (4,5). The dependence of PDE-III
inhibitors on endothelium to produce va-
sodilation is controversial. Stimulation of
nitric oxide (NO) production by PDE-III
inhibitors may be implicated not only be-
cause of their ability to reduce pulmonary
and systemic resistance, but also to inhibit
both smooth muscle cell proliferation and
platelet aggregation (6). Therefore, the ben-
efits of using these drugs could be extended
to the possible prevention of the develop-
ment of “graft disease”.
The aim of the present study was to com-
pare the relaxant response of specimens taken
from the most commonly used vessel grafts,
the internal HMA and the human saphenous
vein (HSV), to three clinically useful vasodi-
lator drugs, diltiazem, dobutamine and amri-
none. We also compared the vasorelaxation
induced by all three drugs in the rat aorta and
related this effect to their inotropic action on
the isolated rat atria. These in vitro animal
experiments permitted us to estimate the
vascular and myocardial modifications that
can be expected at concentrations corre-
sponding to the ED50 for each drug.
Material and Methods
Human sample preparation
The vessels employed in this study were
obtained from patients undergoing primary
coronary artery bypass surgery at the Service
of Cardiothoracic Surgery of the Hospital
San Juan de Dios, Ministerio de Salud de la
Provincia de Buenos Aires, La Plata, Argen-
tina. The preparations could be either saphe-
nous vein or mammary artery and were clas-
sified as surgical specimens and thus ex-
empted from patient consent requirements.
After the end of bypass surgery the remnant
segments were transported to our laboratory
in ice-cold 0.9% NaCl and studied within
24 h.
Rat aorta preparation
Sprague-Dawley female rats (45-60 days
old) were anesthetized with ethyl ether and
the thoracic aorta was removed rapidly. The
vessels were placed on a Petri dish filled
with oxygenated (5% CO2 and 95% O2) Krebs
solution (see composition further on), cleaned
of adherent connective tissue, and cut into 2-
4-mm long rings. Special care was taken not
to damage the endothelial layer or to over-
distend the vessel during this procedure.
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Contractile studies of vessel segments
Contractile responses were determined
in a water-jacketed organ bath filled with a
modified Krebs solution of the following
composition: 130 mM NaCl, 4.7 mM KCl,
1.17 mM Na2HPO4, 1.16 mM MgSO4, 24.0
mM HCO3Na, 1.6 mM CaCl2, and 11 mM
glucose. The organ bath was kept at 37ºC
and bubbled with a mixture of 5% CO2 and
95% O2, pH 7.4. The ring was suspended
gently between two stainless steel wires
that could be separated with a micrometer
to achieve the desired passive force. The
lower wire was fixed to a vertical plastic rod
immersed in the organ bath, while the upper
one was attached to a force transducer (Grass
FT.03D, West Warwick, RI, USA, or Letica
TRI-201, Barcelona, Spain). The output of
the transducer was amplified and fed into
an analog-digital board (DT16EZ, Data
Translation, Inc., Marlboro, MA, USA)
mounted on a desktop computer. On-line
recordings and files for later processing were
obtained with an appropriate software
(Labtech Notebook Pro, Laboratory Tech-
nology Corp., Wilmington, MA, USA). A
passive tension of 2 g was applied, and
the rings were allowed to stabilize for 1 h,
being washed out with fresh solution every
20 min.
High potassium solution was used to elicit
contractions by depolarization of the plasma
membrane. The Krebs solution contained 80
mM KCl and the appropriate reduction in
NaCl in order to keep osmolarity unchanged.
In some experiments, contraction was pro-
duced by exposure to 1 µM norepinephrine
(NE) instead of high potassium. Once con-
tractions reached a steady state force, addi-
tive dose-response curves were constructed
for diltiazem (0.1 nM to 0.1 mM), dobuta-
mine (10 µM to 10 mM) and amrinone (10
µM to 1 mM). Results are reported as per-
cent of the maximal force elicited by 80 mM
KCl and the ED50 value was calculated from
the dose-response curve.
Isolated rat atrium preparation
Male Sprague-Dawley rats (200-250 g)
were used. The rats were anesthetized with
ethyl ether and the heart was quickly re-
moved and placed in bicarbonate-buffered
saline equilibrated with 5% CO2-95% O2 at
room temperature. The spontaneously beat-
ing atria were dissected and the left atrium
was mounted on an organ bath with the free
end connected to a force transducer (Letica
TRI 201). The organ bath contained bicarbo-
nate-buffered saline of the following com-
position: 5 mM KCl, 1 mM MgSO4, 1 mM
NaH2PO4, 111 mM NaCl, 1.35 mM CaCl2,
24 mM NaHCO3, and 11 mM glucose. The
solution was equilibrated with 5% CO2 and
95% O2, pH 7.4, thermostated at 37ºC.
After being attached to the transducer the
atrium was stretched until reaching maximal
developed force and stabilized for 30 min,
with the bath solution being replaced every
10 min. The atrium was paced with an elec-
trical field stimulator at 168 beats/min. After
the stabilization period, additive dose-re-
sponse curves were constructed for diltia-
zem, dobutamine and amrinone. Isometric
contractions were recorded from the ampli-
fied output of the transducer fed to an ana-
log-digital board (see above) mounted on a
desktop computer. Online recordings and
files were obtained with an appropriate soft-
ware (Snapshot Storage Scope, EHM Data
Corporation, Bolingbrook, IL, USA) for later
processing. High speed records (0.25 s/frame)
were used in order to measure peak devel-
oped force (F) and, on its first derivative (dF/
dt), maximal velocity of contraction (+dF/
dtmax) and maximal velocity of relaxation
(-dF/dtmax). The +dF/dtmax/-dF/dtmax ratio was
calculated to evaluate the relative effect of
each intervention on velocities of contrac-
tion and relaxation, with its decrease being
considered evidence of a positive lusitropic
(or relaxant) effect and its increase being
considered evidence of a negative lusitropic
(or antirelaxant) effect (7,8).
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than two groups), and significance was ac-
cepted when P < 0.05. The specific applica-
tion of each method is indicated in the figure
legends.
Results
Atrial contractility and aortic relaxation in
animal experiments
Diltiazem (10 nM to 10 µM, N = 5)
produced a concentration-dependent depres-
sion of atrial contractility and relaxation evi-
denced by the decreases in +dF/dtmax and
-dF/dtmax values, respectively (Figure 1A,B).
At high concentrations of diltiazem a nega-
tive lusitropic effect was indicated by the
significant increase in the +dF/dtmax/-dF/dtmax
ratio (Figure 1C). Rat aortic rings precon-
tracted with 80 mM KCl were relaxed by
diltiazem (10 nM to 0.1 mM, N = 8) with an
ED50 of 0.56 ± 0.26 µM (Figure 1, inset).
Myocardial contractility (+dF/dtmax) was de-
pressed by 30 ± 6% at 0.1 µM.
Dobutamine (0.7 µM to 0.14 mM, N = 9)
increased +dF/dtmax and -dF/dtmax by about
30-40% and did not significantly affect the
+dF/dtmax/-dF/dtmax ratio in the rat atria (Fig-
ure 2A, B and C, respectively). Rat aortic
rings contracted with 80 mM KCl were re-
laxed by dobutamine (0.1 to 0.6 mM, N = 12)
with an ED50 of 88 ± 7 µM (Figure 2, inset),
and the ED50 for aortic relaxation had a
maximal positive inotropic effect on the atria
(Figure 2A).
Amrinone (10 µM to 1 mM, N = 6) did
not have positive inotropic effects on rat
atria at 10 or 100 µM, but elicited similar
percentile increases in +dF/dtmax and -dF/
dtmax at 1 mM, with no significant changes in
the +dF/dtmax/-dF/dtmax ratio (Figure 3A to
C). Aortic rings precontracted with 80 mM
KCl were relaxed by amrinone (10 µM to 1
mM, N = 12) with an ED50 of 69 ± 5 µM
(Figure 3, inset), a dose at which no positive
inotropic effect was detected in isolated rat
atria.
Figure 1. Effects of diltiazem (10 nM to 10 µM, at the time indicated by arrows) on isolated
rat atria (N = 5) paced at 168 beats/min. Data are reported as means ± SEM of the percent
changes from control values recorded at the times indicated. Diltiazem depressed the +dF/
dtmax (A) and -dF/dtmax (B), and at the concentration of 10 µM produced a significant
increase in the +dF/dtmax/-dF/dtmax ratio (C), indicating a negative lusitropic effect. *P <
0.05 compared to time 0 (Student t-test). Inset, ED50 to relax KCl-contracted rat aorta. +dF/
dtmax and -dF/dtmax = maximal velocities of contraction and relaxation, respectively.
Statistical analysis
Data are reported as means ± SEM. Dif-
ferences between means were determined
by the Student t-test for unpaired samples
(two groups) or by analysis of variance (more
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Relaxation in human vessels
Amrinone had a relaxing action on both
KCl- and NE-contracted vessels, as shown
in Table 1. In the three vessels studied, the
ED50 values were significantly lower for NE-
induced contractions than for KCl-induced
contractions. In KCl-induced contractions
only, the relaxation induced by amrinone in
HSV and HMA was significantly less in-
tense than that produced in KCl-contracted
rat aorta (Table 1).
The relaxant effect of diltiazem, dobuta-
mine and amrinone on HSV and HMA rings
precontracted with 80 mM KCl is shown in
Figure 4. Diltiazem relaxed HSV and HMA
with similar ED50 values (0.78 ± 0.28 µM, N
= 10, and 1.70 ± 0.60 µM, N = 4, respec-
tively). Dobutamine was more effective in
relaxing the HMA than the HSV (ED50 of
157 ± 21, N = 5 and 390 ± 91 µM, N = 10,
respectively, P < 0.05).
Discussion
Three vasodilating drugs commonly used
in cardiovascular therapy were compared in
terms of their ability to improve myocardial
performance and to maintain the patency of
the implanted grafts after graft surgery. Two
of the three drugs, dobutamine and amri-
none, relaxed the HSV, and HMA as well as
the rat aorta and improved contractility in an
isolated preparation of rat atria. Diltiazem,
as expected, had a relaxant effect on human
and rat vessels plus a negative inotropic
action on rat atria.
A frequent situation in the postoperative
period of patients receiving coronary grafts
is that their blood pressure must be sup-
ported by administration of vasoconstricting
agents, namely catecholamines. This thera-
py may aggravate the vasospasm that occurs
before or after vascular anastomosis in re-
constructive surgery. In addition, catechol-
amine tolerance results in down-regulation
of beta-1 receptors (9) and long-term cate-
Figure 2. Effects of dobutamine (0.7 µM to 0.14 mM, at the time indicated by arrows) on
isolated rat atria (N = 9) paced at 168 beats/min. Data are reported as means ± SEM of the
percent changes from control values recorded at the times indicated. Dobutamine in-
creased the +dF/dtmax (A) and -dF/dtmax (B) from the lowest concentration employed, but
did not produce any significant change in the +dF/dtmax/-dF/dtmax ratio (C). *P < 0.05
compared to time 0 (Student t-test). Inset, ED50 to relax KCl-contracted rat aorta. +dF/dtmax
and -dF/dtmax = maximal velocities of contraction and relaxation, respectively.
cholamine therapy is often difficult to dis-
continue. Dobutamine is not a solution for
this problem since its effects are mediated by
beta adrenergic receptors; in addition, the
enhancement of both stroke volume and heart
rate that it produces is accompanied by an
increase in myocardial oxygen consumption
of about 30% (10,11). In the paced isolated
rat atrium we found a significant positive
inotropic effect produced by dobutamine.
Dobutamine was less effective in vasodilat-
ing KCl-precontracted HSV than KCl-pre-
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contracted arterial vessels, namely rat aorta
and HMA. Therefore, dobutamine will po-
tentially reduce vasospasm at lower doses in
arterial grafts than in venous grafts. In our
animal experiments dobutamine showed the
advantage of producing a maximal increase
in atrial contractility even at the lowest doses
exhibiting aorta relaxing effects. Since the
ED50 for this effect was similar in rat aorta
and in HMA it is possible that the positive
inotropic effect on human tissue could be
maximally achieved at these doses.
Milrinone treatment for several days has
been successfully used to wean patients from
catecholamine infusion (12). PDE-III inhibi-
tors increase cardiac contractility and induce
vasodilation that lowers the left and right
ventricular filling pressure (13). Amrinone
appears to be a more convenient choice than
dobutamine because the pathway it uses to
increase cAMP in myocytes is independent
of beta adrenoceptor stimulation. In addi-
tion, amrinone predominantly increases
stroke volume and does not affect myocar-
dial oxygen consumption (10,11). In the con-
scious and anesthetized dog, amrinone in-
creases left ventricular performance, a fact
that may be related to positive inotropic and
lusitropic effects (14). Our data for rat tis-
sues show that 1 mM amrinone significantly
enhanced contraction and relaxation of iso-
lated atria while a positive lusitropic effect
could not be detected through a significant
decrease in the ratio values. The ED50 for
aortic relaxation is about 70 µM. These re-
sults agree with those showing that both
PDE-III inhibitors, amrinone and milrinone,
induce larger vasodilatation compared to their
positive inotropic effects (14). However, in
the present experiments the ED50 of amri-
none for relaxing the rat aorta contracted
with high potassium was higher than that
reported for rat aorta contracted with phen-
ylephrine (about 4 µM) and lower than that
necessary to relax rat airway smooth muscle
(360 µM). The vasodilation induced by am-
rinone in human vessels contracted with 80
Figure 3. Effects of amrinone (10 µM to 1 mM, at the time indicated by arrows) on isolated
rat atria (N = 6) paced at 168 beats/min. Data are reported as means ± SEM of the percent
changes from control values recorded at the times indicated. At the highest concentration
employed amrinone increased the +dF/dtmax (A) and -dF/dtmax (B), but did not produce any
significant change in the +dF/dtmax/-dF/dtmax ratio (C). *P < 0.05 compared to time 0
(Student t-test). Inset, ED50 to relax KCl-contracted rat aorta. -dF/dtmax and -dF/dtmax =
maximal velocities of contraction and relaxation, respectively.
%
 C
ha
ng
e 
fr
om
 c
on
tr
ol
40
30
20
10
0
-10
-20
40
30
20
10
0
-10
-20
6
4
2
0
-2
-4
0 5 10 15 20 25 30
Time (min)
123456
123456
123456
123456
123456
123456
123456
150
100
50
0
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
A
B
ED50 for
rat aorta
(µM)
C
Table 1. Relaxant effect of amrinone on precontracted rings of rat aorta, human
saphenous vein and human mammary artery.
Constricting ED50 for amrinone (µM)
agent
Rat aorta Human saphenous vein Human mammary artery
80 mM KCl 69 ± 5 (N = 12) 210 ± 27+ (N = 6) 197 ± 31+ (N = 4)
1 µM NE 41 ± 3* (N = 12) 72 ± 31* (N = 7) 15 ± 5* (N = 4)
*P < 0.05 between KCl- and norepinephrine (NE)-contracted vessels (Student t-test),
+P < 0.05 between human vessels and rat aorta (Kruskal-Wallis ANOVA on ranks plus
Dunn’s test).
*
* *10 µM
0.1 mM 1 mM
*
* *
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mM KCl exhibited ED50 values of about 200
µM, being five times higher than those re-
ported with the clinical use of 10-40 µM
(15,16). However, the ED50 values required
to relax NE-induced contractions were sig-
nificantly lower than these values and close
to the concentrations attained in clinical situ-
ations. Amrinone has both endothelium-de-
pendent and endothelium-independent va-
sodilating effects on human vessels in vivo
(5). We have reported that human vessel
grafts exhibit endothelium-dependent relax-
ation in response to acetylcholine (17), but
we cannot affirm that this response is quan-
titatively equal to that of the vessels in situ.
Therefore, endothelial malfunction cannot
be excluded as an explanation for the appar-
ently lower sensitivity to amrinone of iso-
lated HSV and HMA segments precontracted
with high potassium compared with the sen-
sitivity of aortic segments to this drug. In
addition, most of the vessels were from pa-
tients that showed evidence of hypertension,
hypercholesterolemia and/or atherosclerosis
(18,19), pathologies that often involve at-
tenuated NO-dependent vasodilator re-
sponses (5). The topical use of amrinone to
treat vasospasm in microvascular surgery
could be better than that of lidocaine, a
potent local anesthetic, since amrinone is a
better vasodilator than lidocaine in rat femo-
ral artery contracted with epinephrine (20).
Another beneficial cardiovascular effect of
amrinone is that it deactivates the renin-
angiotensin-aldosterone system, usually stim-
ulated in patients with heart failure (12).
Comparing the relaxant effects of all three
vasodilators tested, we observed that the
ED50 values were always lower for rat aorta
than for human vessels, except for dobuta-
mine that relaxed with similar potency rat
aorta and HMA. These results suggest spe-
cies differences plus a potentially lower re-
sponsiveness to amrinone in human seg-
ments related to NO-dependent mechanisms
of relaxation that may be blunted either by
previous vascular pathology or by surgical
manipulation of segment vessels. Dobuta-
mine and amrinone increased rat atrial con-
tractility at doses at which they had already
achieved 100% of their vasodilatory effect
in rat aorta. The ED50 for the relaxant action
of dobutamine on HMA in vitro seems to be
closer to the ED50 for positive inotropic ef-
fects. Nevertheless, both dobutamine or am-
rinone are proven to be effective dilators of
graft segment vessels contracted by high
KCl depolarization of the membrane and it is
possible to expect a concomitant ameliora-
tion of cardiac performance when they are
used to maintain graft patency in reperfusion
surgery at appropriate concentrations.
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Figure 4. Effects of diltia-
zem (A), dobutamine (B)
and amrinone (C) on hu-
man saphenous veins
(open circles, N = 9, 10
and 6, respectively), hu-
man mammary arteries
(closed circles, N = 4, 5
and 4, respectively) and
rat aortas (squares, N =
8, 12 and 12, respec-
tively) precontracted by
exposure to 80 mM KCl.
Data are reported as
means ± SEM of the per-
cent changes from con-
trol values recorded at
the concentrations indi-
cated. HMA = human
mammary artery, HSV =
human saphenous vein,
RA = rat aorta.
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